TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION

HNM01 在 HIV 感染患者中的试验

• 批准号: 6265432
• 负责人: BRUCE J DEZUBE
• 金额: $ 2.98万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265432
• 关键词: AIDS therapy; CD4 molecule; HIV infections; antiAIDS agent; antiidiotype antibody; clinical research; clinical trial phase I; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; virus replication

1) To assess the toxicity profile and determine the maximum tolerated dose of IV hNM01; 2) investigate the clinical pharmacokinetic parameters for hNM01; 3) assess anti-HIV activity through evaluation of CD4 and viral load measurements; and 4) determine whether human anti-rat antibodies (HARA) and human anti-idiotype antibodies are produced against hNM01.

1)评估IV型hNM01的毒性，确定其最大耐受剂量；2)研究hNM01的临床药动学参数；3)通过评估CD4和病毒载量来评估抗hiv活性；4)确定是否产生针对hNM01的人抗大鼠抗体（HARA）和人抗独特型抗体。